UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by State Street Corp

State Street Corp grew its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 5.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 769,583 shares of the company’s stock after acquiring an additional 42,907 shares during the period. State Street Corp owned about 3.28% of UroGen Pharma worth $9,774,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Point72 Asset Management L.P. raised its position in shares of UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after acquiring an additional 1,337,257 shares in the last quarter. Millennium Management LLC raised its holdings in shares of UroGen Pharma by 2,672.0% during the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after purchasing an additional 1,119,019 shares during the period. Cowen AND Company LLC raised its holdings in shares of UroGen Pharma by 29.1% during the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock worth $35,229,000 after purchasing an additional 472,893 shares during the period. Vestal Point Capital LP acquired a new position in shares of UroGen Pharma in the 3rd quarter valued at about $5,080,000. Finally, Great Point Partners LLC grew its position in shares of UroGen Pharma by 10.9% during the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock valued at $48,767,000 after buying an additional 285,714 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

Analysts Set New Price Targets

URGN has been the topic of several recent research reports. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Friday, December 6th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $43.70.

UroGen Pharma Trading Up 2.0 %

NASDAQ:URGN opened at $11.04 on Friday. UroGen Pharma Ltd. has a 1 year low of $10.26 and a 1 year high of $20.70. The business has a fifty day moving average of $11.92 and a 200-day moving average of $13.76. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The stock has a market cap of $258.93 million, a price-to-earnings ratio of -3.50 and a beta of 1.06.

UroGen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same period in the previous year, the business posted ($0.68) EPS. Equities analysts predict that UroGen Pharma Ltd. will post -3.1 earnings per share for the current year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.